Arterial Remodeling Technologies
Arterial Remodeling wins CE Mark for bioreabsorbable stent
Arterial Remodeling Technologies said it won CE Mark approval in the European Union for its bioreabsorbable stent for treating coronary artery disease.
Analyst speculates Smith & Nephew split | Medtech Wall Street news for the week of Mar. 31, 2014
Terumo inks deal for Arterial Remodeling’s bioresorbable stent
Arterial Remodeling Technologies said it inked a deal with Terumo Corp. (TYO:4543) for its bioresorbable drug-eluting coronary stent that includes an exclusive buyout option.
Cook launches peripheral drug-eluting stent in Australia | Regulatory Roundup
Arterial Remodeling Technologies drums up $8.5 million for bioresorbable stents
Arterial Remodeling Technologies, a French company whose technology was developed in part by the Cleveland Clinic, has raised $8.5 million in venture capital funding to further develop its biodegradable stents.
Fred Cornhill, former chairman of the Clinic’s department of biomedical engineering, worked with researchers at two French institutions to develop the device. Cleveland Clinic maintains an equity stake in the company, according to Chris Coburn, executive director of Cleveland Clinic Innovations.
